Compare SRPT & NAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRPT | NAD |
|---|---|---|
| Founded | 1980 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.8B |
| IPO Year | 1997 | N/A |
| Metric | SRPT | NAD |
|---|---|---|
| Price | $23.85 | $12.18 |
| Analyst Decision | Hold | |
| Analyst Count | 29 | 0 |
| Target Price | ★ $26.23 | N/A |
| AVG Volume (30 Days) | ★ 2.8M | 595.7K |
| Earning Date | 02-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.35% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,413,715,000.00 | N/A |
| Revenue This Year | $13.72 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 47.15 | N/A |
| 52 Week Low | $10.42 | $9.56 |
| 52 Week High | $128.75 | $11.64 |
| Indicator | SRPT | NAD |
|---|---|---|
| Relative Strength Index (RSI) | 64.06 | 60.71 |
| Support Level | $20.86 | $11.94 |
| Resistance Level | $24.12 | $12.13 |
| Average True Range (ATR) | 0.95 | 0.09 |
| MACD | 0.16 | 0.01 |
| Stochastic Oscillator | 92.22 | 98.48 |
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Nuveen Quality Municipal Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempted from regular federal income tax by investing in tax-exempt municipal securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.